mRNA skin cancer vaccine progresses to phase three

The third phase trial of a treatment for melanoma skin cancer using a personalized vaccine based on mRNA technology has been successful. The vaccine is tailored to each patient's tumor. The results showed a reduced risk of disease recurrence or spread, with both companies, Moderna and Merck, planning to submit regulatory applications in the coming months. This treatment represents a significant breakthrough in cancer therapy and is expected to generate annual revenues of up to $3 billion by 2035.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل